October 30th, 2007
Thallion Pharma’s Novel Anti-Cancer (ECO-4601), Passed Phase I/II Clinical Trial
Thallion Pharmaceuticals’ novel anti-cancer drug which offers two modes of action – ECO-4601 – showed positive results from its Phase I/II clinical trial.
According to Pierre Falardeau, Ph.D., chief operating officer at Thallion Pharmaceuticals in Montreal, Canada:
”In 26 patients with advanced solid tumors, treatment with ECO-4601 is safe and well tolerated, including at doses yielding plasma […]
Recent Comments